Company Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.

The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer.

It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Country	United States
Founded	2018
IPO Date	Mar 19, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	49
CEO	Bronson Crouch

Contact Details

Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States
Phone	972 499 3350
Website	instilbio.com

Stock Details

Ticker Symbol	TIL
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$20.00
CIK Code	0001789769
CUSIP Number	45783C101
ISIN Number	US45783C2008
Employer ID	83-2072195
SIC Code	2836

Key Executives

Name	Position
Bronson Crouch	Chairman and Chief Executive Officer
Dr. Sandeep Laumas M.D.	Chief Financial Officer and Chief Business Officer
Dr. Mark E. Dudley Ph.D.	Chief Scientific Officer

Latest SEC Filings

Date	Type	Title
Nov 21, 2024	EFFECT	Notice of Effectiveness
Nov 19, 2024	UPLOAD	Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024	S-3	Registration statement under Securities Act of 1933
Nov 13, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report
Oct 25, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Sep 27, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals

View All SEC Filings